Remission induction in newly diagnosed AML patients aged 55-75 years using a 5 day idarubicin schedule in combination with cytarabine

被引：0
|
作者：
Douer, D
Saven, A
Watkins, K
Gollard, R
Kahn, A
Piro, L
Levine, AM
机构：
[1] UNIV SO CALIF,DIV HEMATOL,LOS ANGELES,CA
[2] SCRIPPS CLIN & RES FDN,DIV HEMATOL,LA JOLLA,CA 92037
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3015 / 3015
页数：1
相关论文
共 37 条
  • [1] PHASE I/II PANOBIDARA STUDY OF PANOBINOSTAT IN COMBINATION WITH IDARUBICIN AND CYTARABINE IN PATIENTS AGED 65 YEARS OR OLDER WITH NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKAEMIA (AML)
    Ocio, E. M.
    Herrera, P.
    Olave, M. T.
    Martinez, M. P.
    Perez-Simon, J. A.
    Brunet, S.
    Oriol, A.
    Mateos, M.
    Sanz, M. A.
    Lopez, J.
    Mateos, M. V.
    San Miguel, J. F.
    [J]. HAEMATOLOGICA, 2014, 99 : 527 - 527
  • [2] Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients
    Gardner, Kelda
    Estey, Elihu H.
    Tong, Weigang
    McCroskey, Robert
    Walter, Roland B.
    Hendrie, Paul C.
    Scott, Bart L.
    Perdue, Andrea M.
    Percival, Mary-Elizabeth M.
    Smith, Heather A.
    Hammer, Cody
    Becker, Pamela S.
    [J]. BLOOD, 2016, 128 (22)
  • [3] Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
    Ocio, Enrique M.
    Herrera, Pilar
    Olave, Teresa
    Brunet, Salut
    Oriol, Albert
    Martinez-Sanchez, Maria-Pilar
    Sanz, Miguel A.
    Mateos, Marta
    Aliseda, Pilar
    Winiger, Ivo J.
    Hardikar, Sushant
    Victoria Mateos, Maria
    Lopez, Javier
    San-Miguel, Jesus F.
    [J]. BLOOD, 2012, 120 (21)
  • [4] High dose idarubicin (HIda) with high dose cytarabine (HiDac) as induction therapy for newly diagnosed patients with AML.
    Maslak, P
    Weiss, M
    Jurcic, J
    Jimenez, J
    Berman, E
    Golde, D
    Scheinberg, D
    [J]. BLOOD, 1998, 92 (10) : 231A - 231A
  • [5] Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years
    Ravandi, Farhad
    Cortes, Jorge
    Faderl, Stefan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Borthakur, Gautam
    Pierce, Sherry
    Brandt, Mark
    Lang, Marites
    Zhang, Weiguo
    Luthra, Rajyalakshmi
    Jones, Dan
    Levis, Mark J.
    Konopleva, Marina
    Andreeff, Michael
    Kantarjian, Hagop M.
    [J]. BLOOD, 2008, 112 (11) : 285 - 285
  • [6] INDOXIMOD IN COMBINATION WITH IDARUBICIN AND CYTARABINE FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): PHASE 1 REPORT
    Emadi, A.
    Holtzman, N. G.
    Imran, M.
    El Chaer, F.
    Koka, M.
    Singh, Z.
    Shahlaee, A.
    Sausville, E. A.
    Law, J.
    Lee, S. T.
    Banerjee, A.
    Rapoport, A.
    Baer, M. R.
    Duong, V. H.
    Munn, D. H.
    Loken, M.
    Kennedy, E.
    Vahanian, N.
    Link, C.
    [J]. HAEMATOLOGICA, 2017, 102 : 375 - 375
  • [7] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [8] A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients
    Christian, Sonia
    Kozma, Kelley E.
    Barath, Stephanie
    Shergill, Ardaman
    Rondelli, Damiano
    Peace, David
    Saraf, Santosh L.
    Oh, Annie Lee
    Sweiss, Karen
    Khan, Irum
    Patel, Pritesh
    Dudek, Arkadiusz
    Quigley, John G.
    [J]. BLOOD, 2018, 132
  • [9] Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Nazha, Aziz
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Huang, Xuelin
    Choi, Sangbum
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Andreeff, Michael
    Estrov, Zeev
    Daver, Naval G.
    Pemmaraju, Naveen
    Du, Mm
    Brandt, Mark
    Faderl, Stefan
    [J]. BLOOD, 2012, 120 (21)
  • [10] Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Nazha, Aziz
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Konopleva, Marina
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Andreeff, Michael
    Du, Min
    Brandt, Mark
    Faderl, Stefan
    [J]. BLOOD, 2011, 118 (21) : 674 - 674
1234